其中，10亿美元的“沉没成本”，直指其B7-H4 ADC药物Felmetatug vedotin的研发终止。B7-H4，这个曾被寄予厚望的ADC新兴靶点，再次迎来一大挫折。 尽管 ...

2025年3月3日，国家药物临床试验登记与信息公示平台官网公示，翰森制药启动了靶向B7-H4抗体偶联药物（ADC）注射用HS-20089（GSK5733584）的首个III期 ...

H.C. Wainwright says that competitor data demonstrate impressive ORR in endometrial cancer, opening a potential opportunity for NetCure’s ...

A few weeks earlier, it tapped the Chinese biotech for a B7-H4 targeted ADC with potential in gynaecological cancers for $85 million upfront and up to $1.5 billion in milestones. MSD and Daiichi ...

NextCure, Inc. has completed cohort 1 of the Phase 1 trial for its cancer treatment candidate, LNCB74 (B7-H4 ADC), in February 2025 and plans to initiate backfill cohorts later in the year.

AZD8205 is a topoisomerase 1 inhibitor (Top1i) ADC that targets B7-H4, an immunoregulatory protein that is highly expressed ...